Nanoscope Therapeutics Inc., a company based in Bedford, Texas, has reported key results from a Phase 2 clinical trial, “STARLIGHT”, at the American Society of… Read More »Nanoscope Therapeutics Inc., have reported clinical trial results from a Phase 2 Stargardt disease study with optogenetic gene therapy.
Principal investigators Dr. Aaron Nagiel, MD, PhD, at Children’s Hospital of Los Angeles, and Dr. Lesley Everett, MD, PhD, MPhil, at the Oregon Health Sciences… Read More »Clinical researchers on X-linked retinoschisis (XLRS) reports the dosing of a first patient in a phase 1 / 2 study.
Researchers at the Department of Ophthalmology, University of California, Irvine and the Structural Biology Research Centre, Vrije Universiteit Brussels, Belgium, have reported the use of… Read More »US & Belgium research team discover a novel “nanobody” (a “mini-antibody”) potentially applicable to retinitis pigmentosa (RP) treatment.
by Dr. Gearóid Tuohy Dear EURETINA Members, A very warm welcome to the September 14th, 2023 edition of EURETINA’s web-based digital magazine, “EURETINA Brief”. EURETINA… Read More »September 14th, 2023 “EURETINA-Brief”© Issue No. 278
Beacon Therapeutics, based in London and Oxford, UK, have recently announced an investment of £96 million (€112 million) to fund the acquisition of AGTC (Applied… Read More »Beacon Therapeutics have announced the acquisition of AGTC (NASDAQ: AGTC), supported by Syncona Ltd and Oxford Science Enterprises.
FDA approval of visual gains and safety of aflibercept (8mg) were announced on August 18th, indicated for the treatment of patients with wet age-related macular… Read More »Aflibercept (8mg) has been approved for wet AMD, diabetic macular edema (DME) and diabetic retinopathy (DR).
Researchers at the Institute of Ophthalmology, University College London and Moorfields Eye Hospital have reported that biomarkers, analysed by OCT scans, have shown reduced thickness… Read More »UCL Institute of Ophthalmology and Moorfields Eye Hospital publish data on OCT scan assessing biomarkers for neurodegeneration.
by Dr. Gearóid Tuohy Dear EURETINA Members, A very warm welcome to the August 28th, 2023 edition of EURETINA’s web-based digital magazine, “EURETINA Brief”. EURETINA… Read More »August 28th, 2023 “EURETINA-Brief”© Issue No. 277
Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), an ophthalmic pharmaceutical company based in California, and the Choroideremia Research Foundation (CRF), a non-for-profit patient organisation focused on the… Read More »Kiora Pharmaceuticals Inc. have announced a partnership with the Choroideremia Research Foundation for novel treatments.
Results of a biosimilar agent (SB15) of aflibercept (Eylea) have reported comparable outcomes between the generic version and the reference drug (aflibercept) for naïve neovascular… Read More »A biosimilar of aflibercept (“SB15”) indicates comparability to the reference drug for neovascular AMD.